Hemophilia Spin Off (Details Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Feb. 01, 2017
Assets and Liabilities Distributed to Bioverativ [Line Items]
Other	$ 41.6	$ 79.0	$ 131.6	$ 166.9
Cost of sales	366.2	370.3	750.8	683.3
Product, net	2,639.7	2,466.0	5,019.8	4,775.4
Hemophilia products
Assets and Liabilities Distributed to Bioverativ [Line Items]
Product, net		$ 205.0	$ 74.4	$ 387.7
Bioverativ
Assets and Liabilities Distributed to Bioverativ [Line Items]
Term of Bioverativ transaction services agreement			12 months
Term of Bioverativ manufacturing and supply agreement			5 years
Cash					$ 302.7
Other	4.0		$ 7.1
Cost of sales	$ 3.7		$ 6.6